A study of the effect of terlipressin with albumin vs only albumin in patients diagnosed with hepatorenal syndrome (HRS)

Background: Hepatorenal syndrome (HRS) is a potentially reversible, functional renal failure that occurs in patients with advanced liver disease. HRS is generally characterized by increased serum creatinine, azotemia, reduced diuresis, increased urine osmolarity, and reduced urine sodium values without signs of organic kidney damage1. AIM: The aim of the study is to investigate the efficacy, adverse effects, and outcomes of Terlipressin with Albumin vs. only Albumin in patients diagnosed with hepatorenal syndrome. Material and methods: A single centred hospital-based descriptive ,observational study was conducted in patients admitted with a diagnosis of hepatorenal syndrome for 18 months (October 2019 to March 2021). A total 80 cases were studied. Results: All the parameters including Total Bilirubin, SGPT ( Serum glutamate pyruvate transaminase ), INR ( Internationalised normalised ratio ) and Serum Albumin were found to be similar ion both the groups except except SGOT (p=0.002) which was found to be significantly lower in Terlipressin +Albumin treatment group (61.89±47.83) compared to only albumin .(96.80±109.30). Those who were treated with Terlipressin +Albumin showed significant decrease in serum creatinine. A significant decrease in serum creatinine was observed at Day 5 (1.73±1.49) from Day 1 (3.47±1.68) making a mean percentage decrease of 50.14%

Relation of carotid intima media thickness (CIMT) with fasting and postprandial triglyceride levels in subjects with type 2 diabetes mellitus: A comparative study

Objectives: The lipid abnormalities seen in Type 2 Diabetes Mellitus (T2DM), especially hypertriglyceridemia, undoubtedly contribute to higher risk of atherosclerotic cardiovascular disease (ASCVD). Carotid intima media thickness (CIMT) measurement is a suitable non-invasive method to detect early changes of atherosclerosis. As atherosclerosis is increasingly being recognized as a postprandial event, the present study is aimed to study the correlation between fasting and postprandial triglyceride levels with CIMT in patients with T2DM. Materials and Method: 106 T2DM patients in the age group 30 to 75 years with duration of initial diagnosis of T2DM ≥ 5years, without ischemic heart disease, cerebrovascular disease and peripheral vascular disease were recruited in this single centre, cross sectional, observational study. CIMT was measured in all patients using B mode ultrasonography. Fasting and postprandial blood glucose levels, glycosylated Hb (HbA1c), renal function tests, fasting and postprandial triglyceride levels (FTG, PPTG), total cholesterol, HDL, LDL and VLDL were measured. Results: The study population was divided into 3 groups based on fasting and postprandial triglyceride levels: Group A (FTG <150 mg/dl, PPTG <200 mg/dl), Group B (FTG <150 mg/dl, PPTG ≥200 mg/dl) and Group C (FTG ≥150mg/dl, PPTG ≥ 200 mg/dl)

A Study of the Effect of Terlipressin with Albumin Vs Only Albumin in Patients Diagnosed with Hepatorenal Syndrome (HRS)

Background: Hepatorenal syndrome (HRS) is a potentially reversible, functional renal failure that occurs in patients with advanced liver disease. HRS is generally characterized by increased serum creatinine, azotemia, reduced diuresis, increased urine osmolarity, and reduced urine sodium values without signs of organic kidney damage1. AIM: The aim of the study is to investigate the efficacy, adverse effects, and outcomes of Terlipressin with Albumin vs. only Albumin in patients diagnosed with hepatorenal syndrome. Material and methods: A single centred hospital-based descriptive ,observational study was conducted in patients admitted with a diagnosis of hepatorenal syndrome for 18 months (October 2019 to March 2021). A total 80 cases were studied. Results: All the parameters including Total Bilirubin, SGPT ( Serum glutamate pyruvate transaminase ), INR ( Internationalised normalised ratio ) and Serum Albumin were found to be similar ion both the groups except except SGOT (p=0.002) which was found to be significantly lower in Terlipressin +Albumin treatment group (61.89±47.83) compared to only albumin .(96.80±109.30). Those who were treated with Terlipressin +Albumin showed significant decrease in serum creatinine. A significant decrease in serum creatinine was observed at Day 5 (1.73±1.49) from Day 1 (3.47±1.68) making a mean percentage decrease of 50.14%